글로벌 D형 간염 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

D형 간염 시장 분석

D형 간염 시장은 만성 D형 간염 감염의 유병률 증가와 치료 옵션의 발전에 힘입어 상당한 성장을 경험하고 있습니다. 전 세계적으로 약 1,500만~2,000만 명이 영향을 받는 것으로 추산되며, 효과적인 항바이러스 요법에 대한 수요가 증가하면서 제약 회사들이 연구 개발에 막대한 투자를 하고 있습니다. 최근 루핀의 테노포비르 알라페나마이드와 안티오스 테라퓨틱스의 새로운 요법과 같은 혁신적인 치료법의 승인은 이 시장의 역동적인 특성을 강조합니다. 또한 활성 부위 중합효소 억제제와 복합 요법을 포함한 새로운 요법에 대한 진행 중인 임상 시험은 치료 효능과 환자 결과를 향상시키는 것을 목표로 합니다. 시장 환경은 또한 서비스가 부족한 지역에서 치료 접근성을 확대하는 데 중점을 둔 파트너십을 포함하여 주요 참여자 간의 협업이 특징입니다. 정부 이니셔티브와 증가하는 의료 지출은 연구 자금을 지원하고 의료 인프라를 개선함으로써 시장 성장을 더욱 지원합니다. D형 간염과 관련 합병증에 대한 인식이 계속 높아짐에 따라 시장은 상당한 확장을 앞두고 있습니다.

D형 간염 시장 규모

글로벌 D형 간염 시장 규모는 2023년에 7억 4,409만 달러로 평가되었으며, 2031년까지 9억 4,259만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 3.00%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

D형 간염 시장 동향

“ 핵산 유사체의 사용 증가”

The hepatitis D market is poised for growth, influenced by increasing awareness of hepatitis D as a significant co-infection with hepatitis B and the need for effective treatment options. One notable trend is the development of nucleos(t)ide analogs that target hepatitis D virus (HDV) replication. For instance, the clinical trials of buprenorphine and tenofovir have shown promising results in suppressing HDV, offering hope for better management of this challenging condition. In addition, ongoing research into therapeutic vaccines aimed at stimulating the immune response against HDV is gaining traction, with companies such as Mycenax Biotech exploring innovative solutions. These advancements, combined with increased global initiatives for hepatitis awareness and education, are driving demand for hepatitis D treatments. As healthcare providers and patients become more informed about hepatitis D's impact, the market is expected to expand, paving the way for new therapies and improved patient outcomes in managing this viral infection.

Report Scope and Hepatitis D Market Segmentation 

Hepatitis D Market Definition

Hepatitis D, also known as delta hepatitis, is a liver infection caused by the hepatitis D virus (HDV). This virus is unique because it can only infect individuals who are already infected with hepatitis B virus (HBV), making it a co-infection rather than a standalone disease. HDV is transmitted through contact with infected blood or bodily fluids, similar to hepatitis B. The infection can lead to more severe liver disease compared to hepatitis B alone, including increased risk of chronic hepatitis, cirrhosis, and liver cancer. Hepatitis D Symptoms can range from mild to severe and may include fatigue, jaundice, abdominal pain, and loss of appetite.

Hepatitis D Market Dynamics

Drivers

• Increasing Prevalence of Hepatitis B

The increasing prevalence of hepatitis B significantly contributes to the demand for hepatitis D treatment, as hepatitis D can only infect individuals already infected with hepatitis B. According to the World Health Organization (WHO), an estimated 296 million people were living with chronic hepatitis B worldwide in 2019, with the highest rates found in regions such as sub-Saharan Africa and East Asia. In these endemic areas, the co-infection rates of hepatitis B and D are notably high. Such interrelationship emphasizes the necessity for comprehensive management strategies that address both infections simultaneously to reduce the risk of severe liver disease and improve patient outcomes. As awareness of the prevalence of these co-infections rises, there is an urgent need for effective diagnostic and therapeutic options tailored to the unique challenges presented by hepatitis D, driving growth in the hepatitis D treatment market.

• Rising Incidence of Intravenous Drug Abuse

The rising incidence of intravenous drug abuse is a significant driver for the global hepatitis D market, as this practice is a key risk factor for hepatitis D virus (HDV) transmission. According to the United Nations Office on Drugs and Crime (UNODC), approximately 11 million people worldwide inject drugs, with a notable increase in regions such as Eastern Europe and Central Asia. Such population is particularly vulnerable to blood-borne infections, including hepatitis B and D, due to the sharing of contaminated needles and syringes. . The interplay between rising intravenous drug use and hepatitis B infection underscores the urgent need for effective prevention and treatment strategies targeting hepatitis D. As healthcare systems recognize this link, there is a growing demand for comprehensive harm reduction programs and antiviral therapies aimed at managing both hepatitis B and D infections among this at-risk population, thereby driving growth in the hepatitis D treatment market.

Opportunities

• Increasing Research and Development (R&D) InvestmentS

Research and Development (R&D) investment in the field of hepatitis D is crucial for advancing new antiviral therapies and vaccine candidates that can significantly improve treatment outcomes. Recent estimates from IQVIA indicates that, the 15 largest pharmaceutical companies invested a record $133 billion in 2021 in R&D expenditure, an increase of 44% since 2016, with a substantial portion directed toward infectious diseases, including hepatitis D. Innovative approaches such as combination therapies are being explored to enhance treatment efficacy and reduce the risk of drug resistance. For instance, the development of therapies combining tenofovir with entecavir has shown promise in clinical trials, with studies indicating a higher rate of virological response in patients co-infected with hepatitis B and D. Such R&D efforts aim to address the existing challenges in managing hepatitis D and to provide innovative solutions that meet the evolving needs of patients, ultimately creating opportunities in the hepatitis D market.

• Increasing Awareness Campaigns

Awareness campaigns focusing on hepatitis D are essential for driving demand for screening and treatment options, as education about the disease significantly influences patient behavior and healthcare-seeking patterns. For instance, initiatives such as World Hepatitis Day, observed annually on July 28, aim to increase global awareness and encourage testing and vaccination. Such campaigns help to inform the public about the risks and consequences of hepatitis D and create a conducive environment for healthcare providers to promote screening and treatment options. By actively participating in or sponsoring these awareness initiatives, companies can position themselves as key players in the market, thereby enhancing their visibility and driving demand for their products and services aimed at managing hepatitis D. Ultimately, broadening opportunities in the market

Restraints/Challenges

• High Treatment Costs

High treatment costs pose a significant barrier to accessing care for patients with hepatitis D, as advanced antiviral therapies and combination treatments often come with hefty price tags that can be unaffordable for many individuals, particularly those in low-income regions. Such financial burden can lead patients to forgo necessary treatment, resulting in delayed interventions that may exacerbate their condition and increase the risk of severe complications, such as liver cirrhosis or hepatocellular carcinoma. Furthermore, individuals without adequate health insurance coverage are disproportionately affected, as they may face out-of-pocket expenses that deter them from seeking timely medical attention. Consequently, hampering the overall market expansion.

• Deterring Regulatory Hurdles

Regulatory hurdles significantly impact the hepatitis D market by prolonging the timeline for obtaining approval for new therapies, which can delay patient access to potentially life-saving treatments. The process often involves rigorous clinical trials, comprehensive data submissions, and extensive review periods, creating a complex environment that can deter pharmaceutical companies from pursuing novel solutions. For instance, the development and approval of new antiviral drugs can take years or even decades, as seen with certain therapies for hepatitis C, which faced prolonged evaluation processes before reaching the market. This lengthy timeline stifles innovation and hinders the availability of advanced treatments for patients who urgently need them. In addition, the evolving regulatory landscape can introduce uncertainties that complicate the planning and funding of clinical trials, discouraging investment in hepatitis D research. As a result, regulatory challenges can create barriers to the timely introduction of effective therapies, limiting treatment options for patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hepatitis D Market Scope

The market is segmented on the basis type, treatment, diagnosis, transmission, end-users, and distribution channel . The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute Hepatitis D
• Chronic Hepatitis D

Treatment

• Interferon Alpha
• Lamivudine
• Liver Transplant
• Others

Diagnosis

• Blood Tests
• Elastography
• Liver Biopsy
• Serologic Testing
• Others

Transmission

• Exposure to Infected Blood
• Contaminated Needles
• Blood and Plasma Product Transfusion
• Others

End-Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Hepatitis D Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, transmission, end-users, and distribution channel  as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the hepatitis D market, primarily driven by the presence of major pharmaceutical companies and robust research and development activities in the region. The increasing prevalence of hepatitis D, coupled with high disposable income levels and significant healthcare expenditure, enables better access to advanced treatments and innovative therapies. In addition, the well-established healthcare infrastructure in North America supports comprehensive patient care, further solidifying its dominance in the hepatitis D market.

아시아 태평양 지역은 2024년부터 2031년까지 상당한 성장을 경험할 것으로 예상되며, 이는 의료 솔루션의 혁신을 촉진하는 연구 개발 활동의 급증에 의해 주도됩니다. 또한, 의료 부문에 대한 투자 증가로 인해 인프라와 첨단 의료 기술에 대한 접근성이 향상되고 있습니다. 나아가, 이 지역 내에서 새로운 시장이 등장하면서 확장을 위한 추가 기회가 생겨 아시아 태평양이 글로벌 의료 환경에서 핵심 참여자로 자리매김하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.  

D형 간염 시장 점유율

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 D형 간염 시장 리더는 다음과 같습니다.

• Biosidus(아르헨티나)
• F. 호프만-라 로슈 유한회사(스위스)
• Zydus 그룹(인도)
• NanoGen 헬스케어 Pvt. Ltd.(인도)
• AMEGA Biotech(아르헨티나)
• MINAPHARM Pharmaceuticals(이집트)
• PROBIOMED SA de CV(멕시코)
• 3SBio 그룹(중국)
• 아이거 바이오파마슈티컬스(미국)
• Arrowhead Pharmaceuticals, Inc. (미국)
• Veru Inc. (미국)
• Anthos Therapeutics, Inc. (미국)
• PharmaEssentia Corporation(대만)
• 레플리코어(캐나다)
• Janssen Pharmaceuticals, Inc. (미국)
• 길리드 사이언스 주식회사(미국)
• 헤테로(인도)
• Aurobindo Pharma(인도)
• Viatris Inc. (미국)
• Apotex Inc. (캐나다)
• ViiV Healthcare 그룹 회사(영국)
• GSK plc (영국)
• 시플라(인도)
• Sun Pharmaceutical Industries Ltd. (인도)
• 머크앤코(미국)

D형 간염 시장의 최신 동향

• 2022년 4월, 국제 바이오제약 회사인 Antios Therapeutics, Inc.는 만성 D형 간염 바이러스 감염을 관리하는 것을 목표로 하는 혁신적인 치료법을 개발했습니다. 최근 미국 특허 및 상표청은 D형 간염 바이러스를 치료하기 위한 포스포라미데이트와 관련된 이들의 응용에 대한 특허를 부여했습니다. 이 특허에는 Antios가 개발한 다양한 치료법 및 프로세스 중 새로운 Active Site Polymerase Inhibitor Nucleotide(ATI-2173)가 포함됩니다.

SKU-66493